Primatene Mist Shortage: What Providers and Prescribers Need to Know in 2026

Primatene Mist (epinephrine inhalation aerosol, 0.125 mg per actuation) remains the only FDA-approved over-the-counter asthma inhaler in the United States. While major medical organizations — including the American Thoracic Society and the American College of Allergy, Asthma and Immunology — have expressed concerns about its OTC availability, many patients continue to rely on it. As a prescriber, it's important to understand the current availability landscape, patient safety considerations, and how to counsel patients effectively.

Current Availability Status of Primatene Mist in 2026

There is no FDA-declared national shortage of Primatene Mist as of 2026. As an OTC product, it is not tracked on the FDA Drug Shortage Database. However, your patients may encounter localized stock-outs at individual pharmacies — particularly during fall allergy season, winter respiratory illness peaks, and in regions where prescription inhaler availability has been intermittent.

Manufactured exclusively by Amphastar Pharmaceuticals with no generic competition, Primatene Mist's supply cannot flex the way multi-source products can. A patient presenting to your office who reports difficulty finding their Primatene Mist is likely experiencing a genuine local stock constraint, not patient error.

Who Is Using Primatene Mist and Why?

Patients using Primatene Mist typically fall into one of several categories:

Uninsured or underinsured patients who cannot afford prescription inhalers and choose the OTC option as a cost-saving measure

Patients with truly mild, intermittent asthma who prefer avoiding a prescription entirely

Former OTC CFC-version users who returned to Primatene Mist when it was reintroduced in 2018

Patients using it as a bridge when their prescription inhaler runs out or is unavailable

The FDA approved Primatene Mist for a "narrow population" of patients with mild, physician-diagnosed intermittent asthma. The agency recognized that for some underserved populations, OTC access provided meaningful benefit. However, the FDA also noted that patients with more severe asthma should be under medical supervision and using guideline-based therapy.

Key Clinical Concerns for Providers

When patients present using Primatene Mist, consider addressing the following:

1. Confirm the Asthma Diagnosis

Primatene Mist requires a physician-confirmed asthma diagnosis per its labeling. Some patients may be self-medicating for COPD, bronchitis, cardiac asthma, or other conditions. Incorrect use can delay appropriate treatment and mask serious underlying pathology.

2. Assess Cardiovascular Risk

Epinephrine acts on both alpha and beta receptors, unlike the selective beta-2 agonism of albuterol. Patients with cardiovascular disease, hypertension, cardiac arrhythmias, or diabetes should use Primatene Mist with caution or be transitioned to a more selective bronchodilator. The label specifically warns that blood pressure or heart rate may temporarily increase.

3. Check for MAOI Use — Contraindication

Primatene Mist is absolutely contraindicated in patients currently taking or who have taken a monoamine oxidase inhibitor (MAOI) within the past 14 days. This includes isocarboxazid, phenelzine, tranylcypromine, and linezolid. The interaction can cause dangerous, potentially life-threatening increases in blood pressure and heart rate.

4. Assess Asthma Severity and Counsel on Limitations

Primatene Mist is approved only for mild, intermittent asthma — defined as symptoms occurring fewer than two days per week, and nighttime symptoms fewer than twice per month. Patients using Primatene Mist more than twice a week almost certainly have asthma that requires step-up therapy. Use this as a clinical flag to re-assess and initiate controller therapy per GINA or NIH guidelines.

Preferred Prescribing Alternatives for Providers to Offer

When transitioning patients from Primatene Mist to prescription therapy, the following options are first-line per current guidelines:

Albuterol (ProAir HFA, Ventolin HFA, generic): First-line SABA for intermittent and persistent asthma; far more lung-selective than epinephrine; generic versions available at low cost; broadly covered by insurance.

ICS + LABA combinations (e.g., Symbicort, Advair, Dulera): For patients with persistent asthma who have been relying on Primatene Mist as a primary treatment with inadequate control.

Inhaled corticosteroids alone (e.g., budesonide, fluticasone): For mild persistent asthma requiring controller therapy.

How to Help Patients Find Primatene Mist When It's Out of Stock

For patients who need Primatene Mist and can't find it locally, medfinder for providers offers a tool to help patients locate medications at pharmacies near them. medfinder contacts pharmacies to check which ones can fill a patient's medication request, then sends results by text. This can help bridge the gap for patients experiencing local stock-outs.

Documentation and Reporting Recommendations

Per guidance from the American Thoracic Society and FDA, providers should report any adverse events related to Primatene Mist use — particularly cardiovascular events, excess emergency department visits, or hospitalizations — to the FDA's MedWatch program. This adverse event data helps the FDA monitor the real-world safety profile of this OTC product.

For a practical guide on helping your patients find Primatene Mist, read: How to Help Your Patients Find Primatene Mist in Stock.